CG
PRAX icon

Cutler Group’s Praxis Precision Medicines PRAX Stock Holding History

Cutler Group’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-160
Closed -$4K – 4177
2023
Q3 		$4K Hold
160
– – ﹤0.01% 2993
2023
Q2 		$2K Hold
160
– – ﹤0.01% 3088
2023
Q1 		$1K Buy
160
+47
+42% +$1.98K ﹤0.01% 3524
2022
Q4 		$4K Hold
113
– – ﹤0.01% 3343
2022
Q3 		$3K Hold
113
– – ﹤0.01% 4016
2022
Q2 		$4K Buy
+113
New +$12.1K ﹤0.01% 3898

Other funds holding PRAX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Cutler Group's PRAX Position: Q4 2023 in Review

Cutler Group sold out of Praxis Precision Medicines (PRAX) in Q4 2023, closing a stake of 160 shares — an estimated $4K sold.

Cutler Group first reported a position in PRAX in Q2 2022 and held it in 6 quarters. The position peaked at $4K in Q3 2023. 60 funds tracked by Wall St. Rank hold PRAX as of Q4 2023.

  • Cutler Group reported no remaining Praxis Precision Medicines position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 160 Praxis Precision Medicines shares in Q4 2023, an estimated $4K.
  • Cutler Group first reported a position in Praxis Precision Medicines in Q2 2022 and held it in 6 quarters.
  • Cutler Group's Praxis Precision Medicines position peaked at $4K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.